A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling.

CONCLUSION: Our results show that inhibition of PDE9 by C36D produces antidepressant- and anxiolytic-like behavioral effects and memory enhancement by activating cGMP/PKG signaling pathway. PDE9 inhibitors may have the potential as a novel class of drug to treat MDD.
PMID: 29722134 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - May 2, 2018 Category: Neuroscience Authors: Huang XF, Jiang WT, Liu L, Song FC, Zhu X, Shi GL, Ding SM, Ke HM, Wang W, O'Donnell JM, Zhang HT, Luo HB, Wan YQ, Song GQ, Xu Y Tags: CNS Neurosci Ther Source Type: research